Biodexa Pharmaceuticals registered the resale of 94,300 ordinary shares representing 1,886 American Depositary Shares after a July 1 fundraise generated $3.5 million in gross proceeds. The offering concerns selling shareholders, so investors should distinguish the registered resale securities from the company’s reported fundraising proceeds.

Key Highlights

  • The ordinary shares have a nominal value of £0.000001 each.
  • Biodexa completed the fundraise on July 1, 2026.
  • The company’s cash balance was £3.23 million at June 30, 2026.

The securities are held by selling shareholders, while the company reported gross proceeds of $3.5 million from a fundraise completed on July 1, 2026. The ordinary shares carry a nominal value of £0.000001 per share.

94,300 Shares Registered

The resale registration covers up to an aggregate of 94,300 ordinary shares. Biodexa Pharmaceuticals (NASDAQ: BDRX) is adding the resale information to its prospectus through a supplement dated September 11, 2026. The prospectus relates to securities that selling shareholders may resell. The prospectus supplement concerns the resale of securities by selling shareholders.

$3.5M Fundraise Completed

The prospectus supplement covers 94,300 ordinary shares and 1,886 American Depositary Shares identified for resale. The company reported a cash balance of £3.23 million at June 30, 2026.

Financial Position At June 30

Research and development costs rose to £2.92 million in the first half of 2026 from £1.67 million in the comparable period. Administrative costs decreased to £1.74 million from £2.38 million. It attributed the administrative-cost decrease primarily to foreign exchange movements. The Serenta trial had enrolled 92 subjects out of a planned 168 by the date of publication. The study was operating across 19 centers in the United States and 10 centers in five European countries. The company also reported that two centers in Canada were expected to begin enrolling in the fourth quarter of 2026.

Resale Registration And Trial Progress

The company’s investigator-initiated Phase 2 trial in non-muscle invasive bladder cancer was fully enrolled at 166 patients.